1. Impact of the sulfonylurea receptor 1 (SUR1) exon 16-3c/t polymorphism on acute hyperglycaemia in type 2 diabetic patients.
- Author
-
Dworacka M, Winiarska H, and Jagodziński PP
- Subjects
- ATP-Binding Cassette Transporters blood, Age of Onset, Body Mass Index, Cytosine, Diabetes Mellitus, Type 2 blood, Diabetic Angiopathies epidemiology, Diabetic Angiopathies genetics, Humans, Middle Aged, Potassium Channels blood, Potassium Channels, Inwardly Rectifying blood, Receptors, Drug blood, Risk Factors, Sulfonylurea Receptors, Thymine, White People, ATP-Binding Cassette Transporters genetics, Diabetes Mellitus, Type 2 genetics, Exons, Hypoglycemia genetics, Polymorphism, Single Nucleotide, Potassium Channels genetics, Potassium Channels, Inwardly Rectifying genetics, Receptors, Drug genetics
- Abstract
Epidemiological data collected over the last few decades have demonstrated the significant role of acute (especially postprandial) hyperglycaemia in the development of macrovascular complications in patients with type 2 diabetes. However, the influence of SUR1 exon 16-3c/t polymorphism on impaired insulin secretion during acute hyperglycaemic episodes has not yet been evaluated. We studied 40 type 2 diabetic patients. Single nucleotide polymorphism in the sulfonylurea receptor gene was examined by means of PCR-RLFP. In every patient, fasting insulin, proinsulin, C-peptide and 1,5-anhydro-d-glucitol concentrations were assayed as markers of insulin secretion, peripheral resistance to insulin, and acute hyperglycaemia. The distribution of SUR1 exon 16-3c/t polymorphism was tt 35%, tc -40%, and cc -25%. By means of analysis of covariance, it was revealed that 1,5-anhydro-d-glucitol plasma levels are associated with SUR1 exon 16-3c/t polymorphism. However, the HOMA(IR) score influenced 1,5-anhydro-d-glucitol levels in plasma at a higher level of statistical power than the genetic variant. Our results suggest that SUR1 exon 16-3c/t polymorphism is only a partial determinant of acute hyperglycaemia-cardiovascular risk factor in type 2 diabetes.
- Published
- 2007
- Full Text
- View/download PDF